Background: The naevoid basal cell carcinoma syndrome (NBCCS) is a therapeutic challenge due to the multiplicity of cutaneous tumours. Photodynamic therapy (PDT) is increasingly used as an alternative treatment for superficial and in some countries nodular basal cell carcinomas (BCC). Objective: To study the safety and efficiency of PDT in NBCCS. Methods: We reviewed retrospectively the evolution of 62 lesions from patients with multiple BCC treated with PDT. Results: The initial response rate (85.4%, 53/62) and recurrence rate (7.5%) appeared comparable to literature values in NBCCS and to those reported in the treatment of sporadic BCC. The clearance rate without recurrence was 79% (49/62), during a mean follow-up period of 13 months. The cosmetic outcome was excellent. Recurrences were found almost 2 years after treatment. Conclusion: PDT is a suitable therapeutic option in the management of NBCCS patients but requires a strict and long follow-up.

1.
Braathen LR, Szeimies RM, Basset-Seguin N, Bissonnette R, Foley P, Pariser D, et al: Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J Am Acad Dermatol 2007;56:125–143.
2.
Fazaa B, Cribier B, Zaraa I, Zermani R, Zeglaoui F, Zouari B, et al: Low-dose X-ray depilatory treatment induces trichoblastic tumors of the scalp. Dermatology 2007;215:301–307.
3.
Babilas P, Karrer S, Sidoroff A, Landthaler M, Szeimies RM: Photodynamic therapy in dermatology – an update. Photodermatol Photoimmunol Photomed 2005;21:142–149.
4.
Horn M, Wolf P, Wulf HC, Warloe T, Fritsch C, Rhodes LE, et al: Topical methylaminolaevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional treatment. Br J Dermatol 2003;149:1242–1249.
5.
Itkin A, Gilchrest BA: δ-Aminolevulinic acid and blue light photodynamic therapy for treatment of multiple basal cell carcinomas in two patients with nevoid basal cell carcinoma syndrome. Dermatol Surg 2004;30:1054–1061.
6.
Oseroff AR, Shieh S, Frawley NP, Cheney R, Blumenson LE, Pivnick EK, et al: Treatment of diffuse basal cell carcinomas and basaloid follicular hamartomas in nevoid basal cell carcinoma syndrome by wide-area 5-aminolevulinic acid photodynamic therapy. Arch Dermatol 2005;141:60–67.
7.
Dijkstra AT, Majoie IM, van Dongen JW, van Weelden H, van Vloten WA: Photodynamic therapy with violet light and topical 6-aminolaevulinic acid in the treatment of actinic keratosis, Bowen’s disease and basal cell carcinoma. J Eur Acad Dermatol Venereol 2001;15:550–554.
8.
Hanneken S, Sterzinger AA, Schulte KW, Reifenberger J: Photodynamische Therapie bei nävoidem Basalzellkarzinomsyndrom. Hautarzt 2005;56:363–364.
9.
Karrer S, Szeimies RM, Hohenleutner U, Heine A, Landthaler M: Unilateral localized basaliomatosis: treatment with topical photodynamic therapy after application of 5-aminolevulinic acid. Dermatology 1995;190:218–222.
10.
Kopera D, Cerroni L, Fink-Puches R, Kerl H: Different treatment modalities for the management of a patient with the nevoid basal cell carcinoma syndrome. J Am Acad Dermatol 1996;34:937–939.
11.
Lane JE, Allen JH, Lane TN, Lesher JL Jr: Unilateral basal cell carcinomas: an unusual entity treated with photodynamic therapy. J Cutan Med Surg 2005;9:336–340.
12.
Schutt F, Staff C, Stein T, Hartschuh W, Dithmar S: Photodynamische Therapie von Lidbasaliomen bei 13-jährigem Patienten mit Gorlin-Goltz-Syndrom. Klin Monatsbl Augenheilkd 2007;224:670–673.
13.
Wang I, Bendsoe N, Klinteberg CA, Enejder AM, Andersson-Engels S, Svanberg S, et al: Photodynamic therapy vs cryosurgery of basal cell carcinomas: results of a phase III clinical trial. Br J Dermatol 2001;144:832–840.
14.
Soler AM, Warloe T, Berner A, Giercksky KE: A follow-up study of recurrence and cosmesis in completely responding superficial and nodular basal cell carcinomas treated with methyl 5-aminolaevulinate-based photodynamic therapy alone and with prior curettage. Br J Dermatol 2001;145:467–471.
15.
Basset-Seguin N: MAL-PDT versus cryotherapy in primary sBCC: results of 36 months follow-up. J Eur Acad Dermatol Venereol 2004;18(suppl 2):412.
16.
Rhodes LE, de Rie M, Enstrom Y, Groves R, Morken T, Goulden V, et al: Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. Arch Dermatol 2004;140:17–23.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.